Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells

  • Authors:
    • Eun-Kyoung Yim
    • Seo-Yun Tong
    • Eun-Mi Ho
    • Jeong-Hoon Bae
    • Soo-Jong Um
    • Jong-Sup Park
  • View Affiliations

  • Published online on: February 1, 2009     https://doi.org/10.3892/or_00000256
  • Pages: 549-557
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previously, we used proteome analysis to identify transforming acidic coiled coil (TACC) 3 as a protein that is down-regulated upon paclitaxel treatment in cervical cancer cells. TACC3 mRNA and protein levels decreased after paclitaxel treatment in a time- and dose-dependent manner, and the transactivation of TACC3 promoter was dramatically diminished by paclitaxel. Importantly, paclitaxel treatment and knockdown of TACC3 by siRNA led to a synergistic enhancement of significant G2/M phase arrest and apoptosis in HeLa cells. In contrast to TACC3-deficient cells, paclitaxel treatment of mTACC3-overexpressing cells failed to induce G2/M phase arrest, cell growth inhibition, and apoptotic cell death. We studied the associated gene in mTACC overexpressed cells using microarray. From these results, numerous genes have been identified as being associated with tumor progression (Ppia, TMSB10, Annexin A2, rab31, prostaglandin E2-EP2, UHRF1), chemoresistance (Akt, Plk-1, MAP kinase) and metastasis (MMP9, PECAM-1) in mTACC3 overexpressed HeLa cells. Thus, TACC3 is thought to be the critical molecule in mediating the anticancer mechanisms of paclitaxel in p53 inactivated cells by inducing G2/M arrest and apoptosis. And our data suggested that the overexpression of TACC3 may be associated with the mechanisms of chemoresistance, tumor progression, cell proliferation and metastasis.

Related Articles

Journal Cover

February 2009
Volume 21 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yim E, Tong S, Ho E, Bae J, Um S and Park J: Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncol Rep 21: 549-557, 2009
APA
Yim, E., Tong, S., Ho, E., Bae, J., Um, S., & Park, J. (2009). Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncology Reports, 21, 549-557. https://doi.org/10.3892/or_00000256
MLA
Yim, E., Tong, S., Ho, E., Bae, J., Um, S., Park, J."Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells". Oncology Reports 21.2 (2009): 549-557.
Chicago
Yim, E., Tong, S., Ho, E., Bae, J., Um, S., Park, J."Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells". Oncology Reports 21, no. 2 (2009): 549-557. https://doi.org/10.3892/or_00000256